Pictet Asset Management (Switzerland)’s Xenon Pharmaceuticals XENE Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$78.3M	Buy	2,032,730 +28,433	+1%	+$1.13M	0.09%	225
2023 Q1	$71.7M	Sell	2,004,297 -115,322	-5%	-$4.26M	0.09%	239
2022 Q4	$83.6M	Sell	2,119,619 -167,746	-7%	-$6.11M	0.12%	208
2022 Q3	$82.6M	Buy	2,287,365 +467,889	+26%	+$16.8M	0.12%	204
2022 Q2	$55.3M	Buy	1,819,476 +494,150	+37%	+$14.9M	0.08%	268
2022 Q1	$40.5M	Buy	+1,325,326	New	+$39.7M	0.05%	355

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s XENE Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Xenon Pharmaceuticals (XENE) stake by 1.4% in Q2 2023, buying an estimated $1.13M and bringing the position to 2,032,730 shares worth $78.3M. The position accounts for 0.09% of the portfolio, ranked #225.

Pictet Asset Management (Switzerland) first reported a position in XENE in Q1 2022 and has held it in 6 quarters since. The position peaked at $83.6M in Q4 2022. 175 funds tracked by Wall St. Rank hold XENE as of Q2 2023.

Pictet Asset Management (Switzerland) held 2,032,730 shares of Xenon Pharmaceuticals worth $78.3M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 28,433 Xenon Pharmaceuticals shares in Q2 2023, an estimated $1.13M.
Xenon Pharmaceuticals made up 0.09% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #225 holding.
Pictet Asset Management (Switzerland) first reported a position in Xenon Pharmaceuticals in Q1 2022 and has held it in 6 quarters since.
Pictet Asset Management (Switzerland)'s Xenon Pharmaceuticals position peaked at $83.6M in Q4 2022.
175 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.